Spatial Chromatin Accessibility Analysis of Intratumor Heterogeneity in Breast Cancer.
Intratumoral heterogeneity (ITH) is a major driver of mortality in breast cancer (BC) patients and a critical factor in the variable therapeutic outcomes observed in BC treatment.
APA
Qian Y, Zhu M, et al. (2026). Spatial Chromatin Accessibility Analysis of Intratumor Heterogeneity in Breast Cancer.. Genomics, proteomics & bioinformatics. https://doi.org/10.1093/gpbjnl/qzag001
MLA
Qian Y, et al.. "Spatial Chromatin Accessibility Analysis of Intratumor Heterogeneity in Breast Cancer.." Genomics, proteomics & bioinformatics, 2026.
PMID
41527290
Abstract
Intratumoral heterogeneity (ITH) is a major driver of mortality in breast cancer (BC) patients and a critical factor in the variable therapeutic outcomes observed in BC treatment. Understanding the mechanisms underlying ITH is essential for advancing both clinical and basic BC research. Chromatin accessibility is critical for regulation of gene expression and cellular identity and plays a central role in shaping ITH and tumor evolution. However, studying chromatin accessibility in situ has been challenging due to the availability of technical platforms. Here, we leveraged the spatial ATAC-seq platform to profile the chromatin accessibility landscape of tumors from six BC patients. Our analyses revealed prominent heterogeneity within tumor regulatory modules and spatial variations in immune cell composition and stromal structures, offering a framework for investigation of the molecular architecture underlying ITH. Moreover, we identified two tumor subclones with potential common origin but distinct immune infiltration conferred by regulatory cascades, suggesting that epigenetic regulation may further contribute to the divergent tumor microenvironments and phenotypic diversity of these subclones. Our study provides novel insights into the molecular mechanisms driving ITH and opens up potential avenues for therapeutic intervention.
같은 제1저자의 인용 많은 논문 (5)
- Metformin hijacks AMPK-ERK1/2 signaling to trigger a pathogenic "selection trap" and thymic atrophy.
- -mutated B-cell acute lymphoblastic leukemia characterized by oncogenic reprogramming of lipid metabolism.
- A Bispecific Peptide-Drug Conjugate Targeting LAG-3 and PD-L1 Harnesses Antitumor Immunity of Macrophages and T Cells.
- LRP-1/CD44-targeted regorafenib nano-delivery system leveraging anti-angiogenesis and synergistic cytotoxicity against peritoneal metastasis of colorectal cancer.
- Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 mG modification.